Gemcabene

Drug Profile

Gemcabene

Alternative Names: CI-1027; PD 072953

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Gemphire Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Caproates; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Lipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemias; Hypertriglyceridaemia
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 30 Jan 2017 Preclinical trials in Non-alcoholic steatohepatitis in Japan (unspecified route) before January 2017
  • 30 Jan 2017 Interim efficacy and adverse events data from the phase IIb trial in Hypercholesterolemia released by Gemphire Therapeutics
  • 30 Jan 2017 Gemphire Therapeutics plans a phase III registration trial in Hypercholesterolemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top